Greenhouse Gas Emissions and Costs of Inhaler Devices in the US

This study assesses mean emissions and costs and estimated total yearly emissions and costs for US-branded inhalers prescribed to Medicare Part D and Medicaid beneficiaries.

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2024-09, Vol.332 (12), p.1017-1019
Main Authors: Tirumalasetty, Jyothi, Miller, Shelie A, Prescott, Hallie C, DeTata, Serena, Arroyo, Anna Chen, Wilkinson, Alexander J. K, Rabin, Alexander S
Format: Article
Language:English
Subjects:
Aerosol Propellants - chemistry
Aerosol Propellants - economics
Asthma - drug therapy
Asthma - economics
Bronchodilator Agents - administration & dosage
Bronchodilator Agents - chemistry
Bronchodilator Agents - economics
Carbon dioxide
Chronic obstructive pulmonary disease
Drug Costs - statistics & numerical data
Drug Prescriptions - economics
Drug Prescriptions - statistics & numerical data
Emissions
Equivalence
Fluorocarbons - chemistry
Fluorocarbons - economics
Greenhouse Effect - economics
Greenhouse Effect - prevention & control
Greenhouse gases
Greenhouse Gases - chemistry
Greenhouse Gases - economics
Humans
Hydrofluorocarbons
Inhalers
Lung diseases
Medicaid - economics
Medicaid - statistics & numerical data
Medicare Part D - economics
Medicare Part D - statistics & numerical data
Nebulizers and Vaporizers - economics
Nebulizers and Vaporizers - statistics & numerical data
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - economics
United States
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study assesses mean emissions and costs and estimated total yearly emissions and costs for US-branded inhalers prescribed to Medicare Part D and Medicaid beneficiaries.
ISSN:0098-7484
1538-3598
1538-3598
DOI:10.1001/jama.2024.15331